Antiviral drug discovery: preparing for the next pandemic
| Autor: | David J. Newman, Rosemary A. Dorrington, Kelly Chibale, Catherine S. Adamson, Marcel Jaspars, Rebecca J. M. Goss |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.drug_class
viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Antiviral Agents Small Molecule Libraries 03 medical and health sciences Drug Discovery Pandemic medicine Humans Molecular Targeted Therapy Pandemics Nucleic Acid Synthesis Inhibitors 030304 developmental biology Biological Products 0303 health sciences SARS-CoV-2 030306 microbiology Drug discovery business.industry COVID-19 Outbreak General Chemistry Virology COVID-19 Drug Treatment Molecular Docking Simulation Coronavirus Protease Inhibitors RNA Viral Antiviral drug business |
| Zdroj: | Chemical Society Reviews |
| ISSN: | 1460-4744 0306-0012 |
| DOI: | 10.1039/d0cs01118e |
| Popis: | Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|